EUVIMEDEUVIMED entdecken
Open Access

Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets

Tamara V Milosevic, Gaëlle Vertenoeil, William Vainchenker, Paul M Tulkens iD, Stefan N Constantinescu, Françoise Van Bambeke iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00533-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Tamara V Milosevic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium. Hauptthemen laut MEDLINE: Oxazolidinones, Megakaryocytes, Blood Platelets, Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ludwig Institute for Cancer Research, Stichting Tegen Kanker (Fondation Contre le Cancer), Salus Sanguinis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxazolidinones (linezolid and tedizolid) adverse reactions include thrombocytopenia, the mechanism of which is still largely unknown. In cultured cells, oxazolidinones impair mitochondrial protein synthesis and oxidative metabolism. As mitochondrial activity is essential for megakaryocyte differentiation and maturation into platelets, we examined whether oxazolidinones impair these processes ex vivo and alter, in parallel, the activity of mitochondrial cytochrome c -oxidase (CYTOX; enzyme partly encoded by the mitochondrial genome) and cell morphology. Human CD34+ cells were isolated, incubated with cytokines (up to 14 days) and clinically relevant oxazolidinone concentrations or in control conditions, and used for (i) clonogenic assays [counting of megakaryocyte (CFU-Mk), granulocyte-monocyte (CFU-GM), burst-forming unit-erythroid (BFU-E) colonies]; (ii) the measure of the expression of megakaryocyte surface antigens (CD34 to CD41 and CD42); (iii) counting of proplatelets; (iv) the measurement of CYTOX activity; and (v) cell morphology (optic and electron microscopy). Oxazolidinones caused a significant decrease in BFU-E but not CFU-Mk or CFU-GM colonies. Yet, the megakaryocytic lineage was markedly affected, with a decreased differentiation of CD34+ into CD41+/CD42+ cells, an abolition of proplatelet formation and striking decrease in the numbers of large polylobulated nucleus megakaryocytes, with a complete loss of intracellular demarcation membrane system, disappearance of mitochondria, and suppression of CYTOX activity. These alterations were more marked in cells incubated with tedizolid than linezolid. These data suggest that oxazolidinones may induce thrombocytopenia by impairing megakaryocytic differentiation through mitochondrial dysfunction. Pharmacological interventions to prevent this toxicity might therefore be difficult as mitochondrial toxicity is most probably inherently linked to their antibacterial activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxazolidinonesMegakaryocytesBlood PlateletsAnti-Bacterial AgentsHematopoietic Stem CellsCell DifferentiationHumansLinezolidMitochondriaCells, CulturedAntigens, CD34Tetrazoles

Stichwörter der Autor:innen

cytochrome c-oxidasemitochondriaoxazolidinone antibioticsthrombocytopenia

Substanzen

OxazolidinonesAnti-Bacterial AgentsLinezolidtedizolidAntigens, CD34Tetrazoles

Autor:innen und Institutionen

  • Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Signal Transduction and Molecular Hematology Unit (SIGN), de Duve Institute, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Ludwig Institute for Cancer Research, Brussels, Belgium.
  • UMR 1170, Institut National de la Santé et de la Recherche Médicale, Université de Paris-Sud & Institut Gustave Roussy, Villejuif, France.
  • WELBIO Department, WEL Research Institute, Wavre, Belgium.
  • Nuffield Department of Medicine, Ludwig Institute for Cancer Research, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Paul M Tulkens, Françoise Van Bambeke

Förderung

  • Ludwig Institute for Cancer Research
  • Stichting Tegen Kanker (Fondation Contre le Cancer)
  • Salus Sanguinis
  • Les avions de Sébastien
  • Actions de recherche Concertée
  • Wel research Institute Welbio
  • Ligue Contre le Cancer (French League Against Cancer)
  • Institut National Du Cancer (INCa)

Zitieren

APA

Milosevic, T. V., Vertenoeil, G., Vainchenker, W., Tulkens, P. M., Constantinescu, S. N., & Van Bambeke, F. (2024). Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00533-24

Vancouver

Milosevic TV, Vertenoeil G, Vainchenker W, Tulkens PM, Constantinescu SN, Van Bambeke F. Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00533-24

BibTeX
@article{Milosevic2024,
  author = {Milosevic, Tamara V and Vertenoeil, Gaëlle and Vainchenker, William and Tulkens, Paul M and Constantinescu, Stefan N and Van Bambeke, Françoise},
  title = {Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00533-24}
}
Kostenlos starten →